Efficacy and tolerability of tropisetron in primary fibromyalgia - A highly selective and competitive 5-HT3 receptor antagonist

Scandinavian Journal of Rheumatology, Supplement

Volumn 29, Issue 113, 2000, Pages 49-54

  Farber L ^a   Stratz, T ^a   Bruckle W ^a   Spath M ^a   Pongratz, D ^a   Lautenschlager J ^a   Kotter I ^a   Zoller B ^a   Peter, H H ^a   Neeck, G ^a   Alten, R ^a   Muller W ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

5 HT3 receptor; Efficacy; Fibromyalgia; Tropisetron

Indexed keywords

PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON; INDOLE DERIVATIVE; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; ADOLESCENT; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PAIN MEASUREMENT; PLACEBOS; PROSPECTIVE STUDIES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS;

EID: 0034534187     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Biochemical abnormalities in fibromyalgia syndrome
2. Plasma tryptophan and other amino acids in primary flbromyalgia: Acontrolled study
3. Serotoninkonzentration im serum bei patienten mit generalisierter tendomyopathie (fibromyalgie) und chronischer polyarthritis
4. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis
5. Elevated cerebro spinal levels of substance P in patients with fibromyalgia syndrome
6. 5-Hydroxytryptamine-facilitated release of substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP
7. An overview of randomized studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting
8. 5-HT3 antagonists in postoperative nausea and vomiting
9. Die generalisierte tendomyopathie (GTM) tell I: Klinik, verlauf und differentialdiagnose
10. BRL 46047A: A highly potent, selective, and long-acting 5-HT3 receptor antagonist with anxiolytic-like properties
11. Efficacy of ICS 205-930, a novel 5-hydroxytryptamin 3 (5-HT3) receptor antagonist in the prevention of migraine attacks. A complex answer to a simple question
12. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population
13. Double blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome
14. Cerebrospinal fluid substance P is elevated in fibromyalgia syndrome
15. Substance P in skeletal muscle of patients with fibromyalgia syndrome
16. 5-HT3-receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord
17. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic